343 related articles for article (PubMed ID: 30784671)
41. Genetic Polymorphisms Affecting Cardiac Biomarker Concentrations in Children with Cancer: an Analysis from the "European Paediatric Oncology Off-patents Medicines Consortium" (EPOC) Trial.
Hellmann F; Völler S; Krischke M; Jamieson D; André N; Bisogno G; Boddy A; Hempel G
Eur J Drug Metab Pharmacokinet; 2020 Jun; 45(3):413-422. PubMed ID: 31981210
[TBL] [Abstract][Full Text] [Related]
42. CMR-derived extracellular volume fraction (ECV) in asymptomatic heart transplant recipients: correlations with clinical features and myocardial edema.
Yuan Y; Cai J; Cui Y; Wang J; Alwalid O; Shen X; Cao Y; Zou Y; Liang B
Int J Cardiovasc Imaging; 2018 Dec; 34(12):1959-1967. PubMed ID: 30056496
[TBL] [Abstract][Full Text] [Related]
43. The utility of routine pre-chemotherapy screening with cardiac gated blood pool scan for patients at low risk of anthracycline toxicity.
Chia PL; Chiang K; Snyder R; Dowling A
J Oncol Pharm Pract; 2018 Jun; 24(4):264-271. PubMed ID: 29284360
[TBL] [Abstract][Full Text] [Related]
44. Effect of candesartan and metoprolol on myocardial tissue composition during anthracycline treatment: the PRADA trial.
Heck SL; Gulati G; Hoffmann P; von Knobelsdorff-Brenkenhoff F; Storås TH; Ree AH; Gravdehaug B; Røsjø H; Steine K; Geisler J; Schulz-Menger J; Omland T
Eur Heart J Cardiovasc Imaging; 2018 May; 19(5):544-552. PubMed ID: 29106497
[TBL] [Abstract][Full Text] [Related]
45. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
46. Assessing for Cardiotoxicity from Metal-on-Metal Hip Implants with Advanced Multimodality Imaging Techniques.
Berber R; Abdel-Gadir A; Rosmini S; Captur G; Nordin S; Culotta V; Palla L; Kellman P; Lloyd GW; Skinner JA; Moon JC; Manisty C; Hart AJ
J Bone Joint Surg Am; 2017 Nov; 99(21):1827-1835. PubMed ID: 29088037
[TBL] [Abstract][Full Text] [Related]
47. Substantial Increase in Myocardial FDG Uptake on Interim PET/CT May Be an Early Sign of Adriamycin-Induced Cardiotoxicity.
Gorla AK; Sood A; Prakash G; Parmar M; Mittal BR
Clin Nucl Med; 2016 Jun; 41(6):462-3. PubMed ID: 26909713
[TBL] [Abstract][Full Text] [Related]
48. Relationship between cardiac mechanical properties and cardiac magnetic resonance imaging at rest in childhood acute lymphoblastic leukemia survivors.
Uwase E; Caru M; Curnier D; Abasq M; Andelfinger G; Krajinovic M; Laverdière C; Sinnett D; Périé D
Int J Cardiovasc Imaging; 2023 Dec; 39(12):2589-2598. PubMed ID: 37728802
[TBL] [Abstract][Full Text] [Related]
49. Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity.
Nabati M; Janbabai G; Baghyari S; Esmaili K; Yazdani J
J Cardiovasc Pharmacol; 2017 May; 69(5):279-285. PubMed ID: 28141699
[TBL] [Abstract][Full Text] [Related]
50. T1 mapping in dilated cardiomyopathy with cardiac magnetic resonance: quantification of diffuse myocardial fibrosis and comparison with endomyocardial biopsy.
aus dem Siepen F; Buss SJ; Messroghli D; Andre F; Lossnitzer D; Seitz S; Keller M; Schnabel PA; Giannitsis E; Korosoglou G; Katus HA; Steen H
Eur Heart J Cardiovasc Imaging; 2015 Feb; 16(2):210-6. PubMed ID: 25246502
[TBL] [Abstract][Full Text] [Related]
51. Cardiac computed tomography-derived myocardial tissue characterization after anthracycline treatment.
Egashira K; Sueta D; Kidoh M; Tomiguchi M; Oda S; Usuku H; Hidaka K; Goto-Yamaguchi L; Sueta A; Komorita T; Oike F; Fujisue K; Yamamoto E; Hanatani S; Takashio S; Araki S; Matsushita K; Yamamoto Y; Hirai T; Tsujita K
ESC Heart Fail; 2022 Jun; 9(3):1792-1800. PubMed ID: 35289088
[TBL] [Abstract][Full Text] [Related]
52. Assessment of early anthracycline-induced cardiotoxicity using segmental strain of cardiac magnetic resonance compared with global strain and functional parameters: an animal study.
Liu JQ; Luo QF; Qi WY; Xiao ZY; Zhang XY; Lan YS; Chen J
Quant Imaging Med Surg; 2023 Sep; 13(9):5511-5524. PubMed ID: 37711795
[TBL] [Abstract][Full Text] [Related]
53. Chronic heart damage following doxorubicin treatment is alleviated by lovastatin.
Henninger C; Huelsenbeck S; Wenzel P; Brand M; Huelsenbeck J; Schad A; Fritz G
Pharmacol Res; 2015 Jan; 91():47-56. PubMed ID: 25462173
[TBL] [Abstract][Full Text] [Related]
54. Cardiac Magnetic Resonance Imaging and Blood Biomarkers for Evaluation of Radiation-Induced Cardiotoxicity in Patients With Breast Cancer: Results of a Phase 2 Clinical Trial.
Speers C; Murthy VL; Walker EM; Glide-Hurst CK; Marsh R; Tang M; Morris EL; Schipper MJ; Weinberg RL; Gits HC; Hayman J; Feng M; Balter J; Moran J; Jagsi R; Pierce LJ
Int J Radiat Oncol Biol Phys; 2022 Feb; 112(2):417-425. PubMed ID: 34509552
[TBL] [Abstract][Full Text] [Related]
55. Doxorubicin-Induced Cardiotoxicity in Collaborative Cross (CC) Mice Recapitulates Individual Cardiotoxicity in Humans.
Zeiss CJ; Gatti DM; Toro-Salazar O; Davis C; Lutz CM; Spinale F; Stearns T; Furtado MB; Churchill GA
G3 (Bethesda); 2019 Aug; 9(8):2637-2646. PubMed ID: 31263061
[TBL] [Abstract][Full Text] [Related]
56. Anthracycline-Induced Atrial Structural and Electrical Remodeling Characterizes Early Cardiotoxicity and Contributes to Atrial Conductive Instability and Dysfunction.
Tan R; Cong T; Xu G; Hao Z; Liao J; Xie Y; Lin Y; Yang X; Li Q; Liu Y; Xia YL
Antioxid Redox Signal; 2022 Jul; 37(1-3):19-39. PubMed ID: 35081742
[No Abstract] [Full Text] [Related]
57. Noncontrast CMR for Detecting Early Myocardial Tissue Injury in a Swine Model of Anthracycline-Induced Cardiotoxicity.
Nakamori S; Jang J; Tschabrunn CM; Pierce P; Goddu B; Rodriguez J; Ngo LH; Tung NM; Manning WJ; Nezafat R
JACC Cardiovasc Imaging; 2019 Oct; 12(10):2085-2087. PubMed ID: 31202765
[No Abstract] [Full Text] [Related]
58. Doxorubicin cardiotoxicity in children: comparison of a consecutive divided daily dose administration schedule with single dose (rapid) infusion administration.
Ewer MS; Jaffe N; Ried H; Zietz HA; Benjamin RS
Med Pediatr Oncol; 1998 Dec; 31(6):512-5. PubMed ID: 9835904
[TBL] [Abstract][Full Text] [Related]
59. Modern Management of Anthracycline-Induced Cardiotoxicity in Lymphoma Patients: Low Occurrence of Cardiotoxicity with Comprehensive Assessment and Tailored Substitution by Nonpegylated Liposomal Doxorubicin.
Olivieri J; Perna GP; Bocci C; Montevecchi C; Olivieri A; Leoni P; Gini G
Oncologist; 2017 Apr; 22(4):422-431. PubMed ID: 28275118
[TBL] [Abstract][Full Text] [Related]
60. Cardiac MRI assessment of anthracycline-induced cardiotoxicity.
Mabudian L; Jordan JH; Bottinor W; Hundley WG
Front Cardiovasc Med; 2022; 9():903719. PubMed ID: 36237899
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
